Valuation : Tonix Pharmaceuticals Holding Corp.

Market Cap 220M 189M 179M 163M 304M 21.04B 307M 2.13B 818M 10.67B 826M 808M 33.89B P/E 2026 *
-1.31x
P/E 2027 * -1.94x
Enterprise Value 220M 189M 179M 163M 304M 21.04B 307M 2.13B 818M 10.67B 826M 808M 33.89B EV / Sales 2026 *
4x
EV / Sales 2027 * 1.98x
Free-Float
99.84%
Yield 2026 *
-
Yield 2027 * -
08/09 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 CI
19/08 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer CI
10/08 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
10/08 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
04/08 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
22/07 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
16/07 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
13/07 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
13/07 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
29/06 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
29/06 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
25/06 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
08/06 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
1 day-4.36%
1 week-8.08%
Current month-12.84%
1 month-2.38%
3 months+12.14%
6 months-13.27%
Current year-21.32%
1 week 12.26
Extreme 12.26
13.48
1 month 11.79
Extreme 11.79
14.5
Current year 9.4
Extreme 9.4
19.95
1 year 9.4
Extreme 9.4
31.55
3 years 6.76
Extreme 6.76
2,976
5 years 6.76
Extreme 6.76
441,279.36
10 years 6.76
Extreme 6.76
602,564,102.56
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Other

Executive/Senior Manager

60,174 0.5110%
27/8/26 Buy

Chief Executive Officer

2,000 0.0170%
20/8/26 Buy

Director

1,000 0.0085%
Change 5-day change 1-year change 3-year change Capi.($)
-4.40%-8.08%-54.46%-99.57% 220M
+0.18%-2.81%+49.34%+89.23% 1,002B
-0.08%-4.11%+51.89%+64.15% 644B
+0.73%-2.91%+19.37%+69.50% 443B
-0.63%-3.09%+29.84%+36.08% 343B
+0.43%-14.61%+11.32%+26.98% 262B
+0.93%-3.19%-1.31%+11.96% 245B
-2.18%-13.95%+37.22%+46.02% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-0.53%-4.36%+25.49%+87.73% 181B
Average -0.52%-4.91%+15.02%+27.39% 352.99B
Weighted average by Cap. +0.04%-4.24%+32.04%+56.06%

Financials

2026 *2027 *
Net sales 55M 47.3M 44.63M 40.66M 76.01M 5.26B 76.7M 532M 205M 2.67B 207M 202M 8.47B 111M 95.36M 89.98M 81.97M 153M 10.6B 155M 1.07B 412M 5.38B 416M 407M 17.08B
Net income -169M -145M -137M -125M -233M -16.13B -235M -1.63B -628M -8.18B -634M -620M -25.99B -164M -141M -133M -121M -227M -15.71B -229M -1.59B -611M -7.97B -617M -603M -25.31B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
11/09/26 USD 12.31 -4.05% 175,965
09/09/26 USD 12.83 -2.51% 167,641
08/09/26 USD 13.16 +0.15% 363,365
04/09/26 USD 13.14 -1.72% 252,492
03/09/26 USD 13.37 -0.07% 264,361
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.83USD
Average target price
42.40USD
Spread / Average Target
+230.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNXP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!